Mirna Therapeutics, Inc.

Bioo Scientific Corporation

Triumvira Immunologics Usa, Inc.

Andreas Bader

David Allen Brown

Kevin Kelnar

Mike Byrom

Christopher W Helsen

Lance Ford

Lubna Patrawala

Ling Wang

Tania Benatar

Jane Zhao

Philbert Ip

Jason F Wiggins

Claudin 18.2 T cell antigen couplers (TACs) polypeptides having (i) an antigen-binding domain that binds Claudin 18.2, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided. Nucleic acids encoding the claudin 18/2 TACs are also provided.

Claudin 18.2 T cell-antigen couplers and uses thereof

A method of treating a subject having liver cancer can include administering a synthetic oligonucleotide to a subject having liver cancer, the oligonucleotide comprising a sequence that is at least 80% identical to at least one of SEQ ID NO:1-12 (e.g., a miR-34 or miR-215 mimic); and administering sorafenib to the subject, wherein the molar ratio of sorafenib:oligonucleotide administered to the subject is in the range of about 10-2000 (e.g., a ratio that provides a superior, for example synergistic or greater than additive, effect).

Sorafenib-microRNA combination therapy for liver cancer

This application describes emulsion formulations containing neutral phospholipids for delivering RNAi, anti-miRNA, or aptamer agents in vivo. The application also relates to methods of making the formulations, and uses of the formulations as delivery agents.

Compositions for the in vivo delivery of RNAi agents

The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-124, using miR-124 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.

MiR-124 regulated genes and pathways as targets for therapeutic intervention

Growing community of inventors

Austin, TX, United States of America

Andreas Bader